Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Tagrisso osimertinib Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Active
Tagrisso Osimertinib Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Tagrisso osimertinib Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Takhzyro lanadelumab Hereditary angioedema, prevention Reimburse with clinical criteria and/or conditions Complete
Taltz ixekizumab Arthritis, psoriatic Reimburse with clinical criteria and/or conditions Complete
Taltz Ixekizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Taltz ixekizumab Ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Talvey talquetamab Relapsed or refractory multiple myeloma Active
Talzenna talazoparib Metastatic castration-resistant prostate cancer (mCRPC) Suspended
Talzenna talazoparib Breast Cancer Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed